FDA Approves Adjuvant Pembrolizumab for Stage IB-IIIA NSCLC
Results from the phase 3 PEARLS/KEYNOTE-091 trial have led to the FDA approval of adjuvant pembrolizumab for the treatment fully resected NSCLC.
Results from the phase 3 PEARLS/KEYNOTE-091 trial have led to the FDA approval of adjuvant pembrolizumab for the treatment fully resected NSCLC.
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
With an FDA orphan drug designation now granted to IGNK001, clinical trials investigating the agent in acute myeloid leukemia are planned to initiate in the…
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Sumanta Kumar Pal, MD, FASCO, reviews data from the TIVO-3 study investigating tivozanib in patients with advanced renal cell carcinoma, and the panel offers its…
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging…
Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other…
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Dr. Bose discusses his perspective on quality-of-life preservation for his patients with myelofibrosis, including the symptoms that have the most negative impact on patients’ quality…
Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.